Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.

Wo JM, Ejskjaer N, Hellström PM, Malik RA, Pezzullo JC, Shaughnessy L, Charlton P, Kosutic G, McCallum RW.

Aliment Pharmacol Ther. 2011 Mar;33(6):679-88. doi: 10.1111/j.1365-2036.2010.04567.x. Epub 2011 Jan 7.

2.

Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study.

Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen LC, Sarosiek I, Søfteland E, Nowak T, Pezzullo JC, Shaughnessy L, Kosutic G, McCallum R.

Neurogastroenterol Motil. 2010 Oct;22(10):1069-e281. doi: 10.1111/j.1365-2982.2010.01519.x. Epub 2010 Jun 28.

PMID:
20524987
3.

Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis.

Ejskjaer N, Vestergaard ET, Hellström PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L, Kosutic G.

Aliment Pharmacol Ther. 2009 Jun 1;29(11):1179-87. doi: 10.1111/j.1365-2036.2009.03986.x. Epub 2009 Feb 27.

4.

A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.

Ejskjaer N, Wo JM, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L, Malik RA, Hellström PM, Mondou E, Quinn J, Rousseau F, McCallum RW.

Neurogastroenterol Motil. 2013 Feb;25(2):e140-50. doi: 10.1111/nmo.12064. Epub 2012 Dec 23.

PMID:
23279217
5.

Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis.

McCallum RW, Lembo A, Esfandyari T, Bhandari BR, Ejskjaer N, Cosentino C, Helton N, Mondou E, Quinn J, Rousseau F; TZP-102 Phase 2b Study Group.

Neurogastroenterol Motil. 2013 Nov;25(11):e705-17. doi: 10.1111/nmo.12184. Epub 2013 Jul 15.

PMID:
23848826
6.

The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.

Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D, Zinsmeister AR.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1453-1459.e4. doi: 10.1016/j.cgh.2013.04.019. Epub 2013 Apr 30.

7.
8.

The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial.

Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ.

Dis Colon Rectum. 2010 Feb;53(2):126-34. doi: 10.1007/DCR.0b013e3181b54166.

PMID:
20087086
9.

Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics.

Stapleton J, Wo JM.

Gastrointest Endosc Clin N Am. 2009 Jan;19(1):57-72, vi. doi: 10.1016/j.giec.2008.12.008. Review.

PMID:
19232281
10.

Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis.

Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T.

Aliment Pharmacol Ther. 2005 Nov 1;22(9):847-53.

11.

Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.

Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT.

Gastroenterology. 2017 Nov;153(5):1240-1250.e2. doi: 10.1053/j.gastro.2017.07.035. Epub 2017 Jul 29.

PMID:
28760384
12.

Nausea and vomiting in diabetic and idiopathic gastroparesis.

Cherian D, Parkman HP.

Neurogastroenterol Motil. 2012 Mar;24(3):217-22, e103. doi: 10.1111/j.1365-2982.2011.01828.x. Epub 2011 Nov 27.

PMID:
22118574
13.

Itopride and pantoprazole outcomes in diabetic gastroparesis trial (IPOD trial).

Venkatesh V, Kulkarni KP.

J Indian Med Assoc. 2008 Dec;106(12):814-5.

PMID:
19370958
14.
15.

Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group.

Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A.

Clin Ther. 1998 May-Jun;20(3):438-53.

PMID:
9663360
16.

Management of diabetic gastroparesis.

Mukhopadhyay P, Basu AK.

J Indian Med Assoc. 2005 Mar;103(3):184, 186. Review.

PMID:
16173296
17.

Spectrum of gastroparesis in children.

Waseem S, Islam S, Kahn G, Moshiree B, Talley NJ.

J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):166-72. doi: 10.1097/MPG.0b013e31824cf06e.

PMID:
22314391
18.

Ghrelin as a target for gastrointestinal motility disorders.

Greenwood-Van Meerveld B, Kriegsman M, Nelson R.

Peptides. 2011 Nov;32(11):2352-6. doi: 10.1016/j.peptides.2011.03.014. Epub 2011 Mar 29. Review.

PMID:
21453735
19.

Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation.

Brand RE, DiBaise JK, Quigley EM, Gobar LS, Harmon KS, Lynch JC, Bierman PJ, Bishop MR, Tarantolo SR.

Lancet. 1998 Dec 19-26;352(9145):1985. No abstract available.

PMID:
9872252
20.

Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.

Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, White J, Currie M, Gottesdiener K, Stoner E; RM-131-004 Trial Group.

Gastroenterology. 2016 Jul;151(1):87-96.e6. doi: 10.1053/j.gastro.2016.03.038. Epub 2016 Apr 4.

PMID:
27055601

Supplemental Content

Support Center